Celltrion begins development of ‘Corona 19’ treatment

 Celltrion has begun to develop a new treatment for coronavirus infection (corona19).On the 19th, Celltrion announced that it was selected as a priority negotiator in the ‘Finding New Non-clinical Antibody Candidates for New Coronavirus Treatment 2019’ bid by the Center for Disease Control and Prevention.
Celltrion has been focusing on the development of corona19 therapeutic antibodies based on existing influenza multi-antibody new drugs and experience in developing antibodies for the treatment of MERS (Middle East Respiratory Syndrome). Currently, company-wide researchers are working on developing a 24-hour treatment.Celltrion said, “We plan to put all our capabilities into the development of therapeutics by completing the establishment of a collaborative system with the Centers for Disease Control and Prevention.”